SUU, Alm.del - 2020-21 - Endeligt svar på spørgsmål 1143: Spm. om en opgørelse over vaccineteknologier med udspring i offentlig forskning, som efterspørges af forskere i andre lande og udvikles i samarbejde med forskere i andre lande, til uddannelses- og forskningsministeren

Sundhedsudvalget 2020-21
SUU Alm.del
Offentligt

Bilag

Bilag 1

–

svar på SUU alm. del spørgsmål 1143

Tabel 1: Opgørelse over internationale forskningsprojekter

Forskningsinstitution

Navn på forskningsprojekt

Samarbejdsparts institution/

organisation

Hjemsted (land)

Dato for projektaftale

Københavns Universitet

Amager og Hvidovre Hospital

CelCradleTM System Trial Agreement,

Terms, and Conditions - HCV Vaccine

Development (inactivated virus vaccine)

Mutual Non Disclosure Agreement

–

SARS-CoV-2 and HCV Vaccine Devel-

Esco Aster

Singapore

01-05-2020

Uddannelses- og

Forskningsministeriet

Forsknings- og Innovationspolitik

Tyskland

09-04-2018

Børsgade 4

Postboks 2135

1015 København K

Tel. 3392 9700

www.ufm.dk

Østrig

01-04-2020

CVR-nr. 1680 5408

opment (inactivated virus vaccines)

Research Cooperation Contract: Chro-

matographic Purification of Inactivated

Cell Culture Derived HCV

Animal cell culture based viral vaccine

production. HCV and SARS-CoV-2

NDA and MTA relating to cell line used

for SARS-CoV-2 vaccine development

Nuvonis

(inactivated virus vaccine)

Capsid-like particles decorated with the

AdaptVac ApS (DK)

Eberhard Karls Universität (DE)

Universitaetsklinikum Tübingen

(DE)

Prevent-nCoV (H2020 Research & Inno-

vation Action)

ExpreS2ion Biotechnologies ApS

(DK)

Nederlandene

Tyskland

01-04-2020

University of Applied Sciences

(Giessen)

Max Planck Institute for Dynam-

ics of Complex Technical Sys-

tems

Tyskland

01-05-2020*

23. juni 2021

Esco Aster

Singapore

12-06-2018

Københavns Universitet

Amager og Hvidovre Hospital

Københavns Universitet

Amager og Hvidovre Hospital

Københavns Universitet

Amager og Hvidovre Hospital

Københavns Universitet

Amager og Hvidovre Hospital

Københavns Universitet

Herlev og Gentofte Hospital

SARS-CoV-2 receptor-binding domain

elicit strong virus neutralization activity

SUU, Alm.del - 2020-21 - Endeligt svar på spørgsmål 1143: Spm. om en opgørelse over vaccineteknologier med udspring i offentlig forskning, som efterspørges af forskere i andre lande og udvikles i samarbejde med forskere i andre lande, til uddannelses- og forskningsministeren

Wageningen University (NL)

Academisch Ziekenhuis Leiden

(NL)

Stichting Katolieke Universiteit -

Radboud University Medical Cen-

ter (NL)

A phase 3, randomized, double- or ob-

server-blinded, placebo-controlled trial to

Nordsjællands hospital

evaluate the efficacy and safety of a res-

piratory syncytial virus (RSV) prefusion

fsubunit vaccine in infants born to women

vaccinated during pregnancy

SARS-CoV-2 vaccination strategies in

Rigshospitalet

previously hospitalised and recoved

COVID-19 patients (VATICO),

Syddansk Universitet

Samarbejde vedr. E. coli strains

Bandim Health Projekt

Samarbejdsaftale vedr. projektet ”Mu-

Syddansk Universitet

lige bivirkninger ved HPV vaccine blandt

nordiske piger og drenge: Påvirker det

uddannelsesforløbet?”

Development of AAVLP vaccine plat-

form.

Aalborg Universitet

Development of Vitiligo vaccine, Head

and Neck cancer vaccine, HIV vaccine,

INSIGHT network (funded by

NIAID and NIH)

GSK Vaccines Srl

Guinea Bissau (stat)

Tampere University Foundation sr

Norwegian Institute of Public

Health

Norge

USA

2021**

Pfizer

USA

29-06-2020

Italien

Guinea Bissau

03-06-2020

N/A

Finland

15-06-2020

For Pan-Coronavirus vaccine and

Pan-Ebolavirus vaccine collabora-

tion with Stony Brook university

USA and John Jay CUNY college

USA

01-01-2017

HPV vaccine, Pan-Corona virus vaccine of Criminal Justice New York,

USA.

and Pan Ebola virus vaccine

Side

2/5

Imperial college of science tech-

nolology and medicine (Impe-

rial);

Statens Serum Institut

Developing a Chlamydia Trachomatis

vaccine

— TracVac’

London school of hygiene and

tropical medicine (LSHTM);

Commissariat a l energie

atomique et aux energies alter-

natives (CEA)

Statens Serum Institut

European Vaccine Research and Devel-

opment Infrastructure

—

TRANSVAC2

POR TB consortium; Phase 2 trial to de-

Statens Serum Institut

termine efficacy of the multistage vac-

cine H56:IC31 for Prevention Of Recur-

rent TB disease

A dual function TB subunit vaccine de-

signed for non-interference with BCG

Statens Serum Institut

and

post-exposure activity

Eliciting lung-localized CD4 T cell re-

Statens Serum Institut

sponses against Mycobacterium tuber-

culosis in preventive and post-exposure

settings

Statens Serum Institut

Novel vaccine vectors to resist patho-

gen challenge’ — ‘VacPath’

Coordinator: Universiteit Utrecht

+ 7 andre partnere

Holland

01-01-2019

Seattle Children's Research In-

stitute (NIH midler)

USA

22-08-2017

Seattle Children's Research In-

stitute (NIH midler)

USA

01-12-2017

European vaccine initiative

EWIV (EVI) + 25 andre partnere

International AIDS Vaccine Initi-

ative, South Africa + 6 andre

partnere

Tanzania

Tyskland

01-05-2017

01-03-2017

Frankrig

Sydafrika

01-11-2017

Statens Serum Institut

Rapid evaluation of Plasmodium falcipa- Coordinator: Université des Sci-

rum transmission Blocking Vaccine

ences, des Techniques et des

Mali

01-01-2019

Side

3/5

(PfTBV) candidates through enhanced

African Resource Centers (ARC) for in-

tegration into malaria control and elimi-

nation

—

PfTBV

Statens Serum Institut

A nanovaccine Approach for the treat-

ment of

Pancreatic Cancer’ — ‘PAVE’

Nanobodies and antibodies against

2019-nCoV’

— ‘CoroNAb’

Recombinant CSP Bill & Melinda Gates

Statens Serum Institut

Foundation funding (contract no.: INV-

003390)

Optimizing a deployable high efficacy

Statens Serum Institut

malaria vaccine (H2020 contract no.:

733273)

Functional immune-genetic correlates of

Statens Serum Institut

malaria immunity. Danish Ministry of

Foreign Affairs (DFC file no.14-P01-

GHA)

Development of

“27-383H-CSP” P. falci-

Statens Serum Institut

parum circumsporozoite protein

(rPfCSP) for non-clinical use L. lactis.

PATH

Statens Serum Institut

Process development and formulation

studies of R0.6C. PATH

Development of P. falciparum UIS 3

constructs in L. lactis. PATH

Technologies de Bamako

(USTTB) + 7 andre partnere

Coordinator: Percuros BV + 13

andre partnere

Koordinator: Karolinska Institutet

+ 3 andre partnere

Holland

01-10-2019

Statens Serum Institut

Sverige

01-04-2020

Coordinator: SSI

N/A

01-11-2019

Coordinator: Oxford

01-01-2017

Coordinator: The Noguchi Me-

morial Institute for Medical Re-

Ghana

01-01-2016

Coordinator: SSI

Ikke oplyst

01-02-2018

Coordinator: SSI

N/A

01-12-2018

Statens Serum Institut

Coordinator: SSI

N/A

11-04-2018

Side

4/5

Construct development and pilot pro-

Statens Serum Institut

duction of a Glideosome-associated

protein 40 (GAP40) in grampositive bac-

teria and yeast. PATH

Broad Influenza Virus VAccine

Statens Serum Institut

(BROADWA-II) /TRANSVAC2 transna-

tional access

Broad Influenza Virus VAccine

Statens Serum Institut

(BROADWA-IIa) /TRANSVAC2 transna-

tional access

OUH / Region Syddanmark

Sugar-modified Vaccine Epitopes; ex-

ploration and Trans

Study MEQ00065

–

MenACYW conju-

gate vaccine: Meningococcal Polysac-

OUH / Region Syddanmark

charide (Serogroups A, C, W and Y)

Tetanus Toxoid

Conjugate Vaccine

OUH / Region Syddanmark

Influenza vaccination After Myocardial

Infarction (IAMI) trial

School of Medical Sciences, Öre-

bro University

Sverige

01-07-2017

Sanofi Pasteur

Frankrig

06-06-2019

Commissariat a l’energie

atomique et aux energies alter-

natives (CEA)

Commissariat a l’energie

atomique et aux energies alter-

natives (CEA)

GlyProVac, epitopic GmbH,

Fraunhofer Gesellschaft

Tyskland

03-11-2020

Frankrig

02-11-2019

Frankrig

01-06-2018

Coordinator: SSI

Ikke oplyst

17-01-2018

* Kontrakten er ved at blive afsluttet. Vil blive dateret tilbage til maj 2020

** Forventet opstart i 2021

Side

5/5